Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Artios logo — Taking control of the DNA Damage Response (DDR)

Artios

Taking control of the DNA Damage Response (DDR)

Founded 2016 United Kingdom Cambridge, United Kingdom 128 employees Series C Total: $230.00M Biopharma, Biotechnology +1

General Information

Company Name Artios
Founded Year 2016
Location United Kingdom Cambridge, United Kingdom
Employees 128
Industries Biopharma, Biotechnology, Medical Devices
Funding Stage Series C
Business Model B2B, B2D
Revenue Model Licensing, Performance Based, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Artios. To contact Artios, visit artios.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Artios compare?

A PDF of Artios and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Artios soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Artios

Artios, founded in 2016, is a UK-based biopharma innovator prominently focused on the DNA Damage Response (DDR) pathway to combat cancer. With their proprietary DcoDeR platform, Artios leverages its expertise in DNA damage biology and drug discovery to develop targeted therapies addressing high unmet needs across solid tumor indications. The company's robust pipeline includes breakthroughs like the ATR inhibitor, ART0380, and the Polθ inhibitor, ART6043, which can be utilized as monotherapy or in combination treatments.

Strategic collaborations with top institutions such as Cancer Research UK and The Institute of Cancer Research enhance their research endeavors. The company’s latest financial achievement, a £110.00M Series C investment secured in July 2021, involved notable investors including Pfizer Venture Investments and RTW Investments. Artios presents a compelling opportunity for investors seeking impactful advancements in oncology therapeutics.

Business keywords: DNA Damage Response, Cancer Treatment, Drug Discovery, DDR Pathways, ATR Inhibitor, Polθ Inhibitor, Oncology Drug Pipeline, Research Collaboration, Solid Tumour Indications, Monotherapy, Combination Treatments, Cancer Research, Novel Therapies, Biopharmaceutical

Services & Products

Development of DDR-based cancer treatments
Clinical research and trials
Drug discovery and development
Innovative cancer therapeutic pipelines

Target Customers

Patients with hard-to-treat solid tumors Oncologists and cancer treatment centers Pharmaceutical partnerships Biotechnology researchers

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series C £110.00M 10
Andera Partner Arix Bioscience CaaS Capital Management
Andera Partner, Arix Bioscience +8
27 Jul 2021
Venture Round $30.00M -
03 Dec 2020
Series B £65.00M -
10 Aug 2018
Series A £25.00M -
21 Sep 2016
Seed Round Undisclosed -
06 Sep 2016

Latest News

View All
French BioTech company ErVimmune raises €17 million to tackle hard-to-treat cancers — Eu-startups
French BioTech company ErVimmune raises €17 million to tackle hard-to-treat cancers
Eu-startups Jan 21, 2026
Amgen acquires Oxford-based Dark Blue in deal worth up to €718 million to advance leukemia programme — Eu-startups
Amgen acquires Oxford-based Dark Blue in deal worth up to €718 million to advance leukemia programme
Eu-startups Jan 07, 2026
Swiss BioTech FoRx Therapeutics closes €42 million for next-generation DNA repair cancer therapy — Eu-startups
Swiss BioTech FoRx Therapeutics closes €42 million for next-generation DNA repair cancer therapy
Eu-startups Dec 18, 2025
SME neobank Allica Bank tops the inaugural Sifted 100: UK & Ireland Leaderboard — Sifted
SME neobank Allica Bank tops the inaugural Sifted 100: UK & Ireland Leaderboard
Sifted Nov 23, 2025
5 UK scaleups enter TECH5 — the ‘Champions League of Tech’ — Thenextweb
5 UK scaleups enter TECH5 — the ‘Champions League of Tech’
Thenextweb May 12, 2025
Fintechs dominate list of UK and Ireland’s fastest growing startups — Sifted
Fintechs dominate list of UK and Ireland’s fastest growing startups
Sifted Mar 27, 2024

Artios Alternatives & Competitors

View All Alternatives
Artios vs
Prelude Therapeutics
Prelude Therapeutics United States

Precision Oncology, Redefined.

Post-IPO Equity
126 employees
Biopharma, Biotechnology
Compare Artios vs Prelude Therapeutics
Artios vs
VRise Therapeutics, Inc.
VRise Therapeutics, Inc. United States

A Precision Oncology Company

5 employees
Biopharma, Biotechnology
Compare Artios vs VRise Therapeutics, Inc.
Artios vs
Onchilles Pharma
Onchilles Pharma United States

Developing drug candidates that have the potential to be broadly effective against a wide range of c...

Series B
10 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Artios

Taking control of the DNA Damage Response (DDR)
Artios was founded in 2016.
Artios is headquartered in Cambridge, United Kingdom.
Artios operates in Biopharma, Biotechnology and Medical Devices. Its work centres on DNA Damage Response, Cancer Treatment, Drug Discovery and DDR Pathways. Its customers include Patients with hard-to-treat solid tumors, Oncologists and cancer treatment centers and Pharmaceutical partnerships.
Artios has a B2B and B2D business model. Its revenue comes from Licensing, Performance Based and Project Based.
Artios has approximately 128 employees.
Artios has completed 5 funding rounds, raising a total of $230.00M. The latest funding stage is Series C.
Artios offers: Development of DDR-based cancer treatments, Clinical research and trials, Drug discovery and development, Innovative cancer therapeutic pipelines.
Top alternatives and competitors to Artios include Prelude Therapeutics, VRise Therapeutics, Inc., Onchilles Pharma, Arcus Biosciences, TFC Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Artios and Prelude Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Artios, https://bouncewatch.com/company/artios-pharma, updated 2 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout